Hey there, community ✌️
Today I’d like to introduce you to another candidate from my watchlist. Yesterday, $LGND (+2.41%) it was the royalty sector’s turn; today we’re focusing on medical technology! 🩺
For that, we’re turning our attention to Japan 🇯🇵 today, and I’ll be introducing you to the “mastermind” behind the medtech sector.
At the request of @PikaPika0105 , I put this presentation together on the fly and will try to sell this stock to him—and maybe one or two of you—today. 😏😂
Let’s go! 🚀
🧬 Asahi Intecc $7747 (+1.42%) : The invisible mastermind behind global surgery
Asahi Intecc $7747 (+1.42%) is not a conventional medical technology company that markets directly to patients. It is the global technological monopolist in the field of ultra-fine wire technology. While other companies sell catheters or stents under their own brand names, Asahi supplies the critical, irreplaceable “inner workings” for these products. Its proprietary manufacturing process allows it to bend wires as thin as a human hair while enabling absolute control (torque transmission)—this is the “high-fidelity connection” between the surgeon and the surgical site.
1. The Business Model: The Triad of Wire Dominance 🔬⚙️📈
Asahi controls the entire process of minimally invasive surgery through three pillars:
Core Technology (Only-One Manufacturing): Asahi masters the integration of metal and polymer technologies at the microscopic level. They don’t just produce wire; they engineer precision of movement. In cardiology, their guidewires are the global gold standard—when a surgeon clears a complicated blockage, they reach for Asahi almost without hesitation.
The OEM software layer (partnerships): The largest medtech giants (Boston Scientific $BSX (+1.06%) , Medtronic $MDT (+0.43%) , Edwards Lifesciences $EW (-0.48%) are not competitors, but paying partners. They rely on Asahi’s precision components to make their own catheter systems marketable in the first place. Asahi $7747 (+1.42%) is thus “embedded” in every major medtech ecosystem.
Global Expansion & Vertical Integration: Asahi $7747 (+1.42%) is aggressively expanding into its own end products (complete catheter systems) to capture the margins previously held by intermediaries. By focusing on robotic surgery and neurovascular procedures, the company is securing access to the fastest-growing fields in medicine.
2. Key Figures (Q3 2026 / FY2026) 📊
Market Capitalization: approx. 890–900 billion JPY (listed on the TSE Prime Market).
Revenue growth: Structural organic growth of 11–14% p.a. (in local currency), driven by demographic changes and the global shift from open surgery to minimally invasive procedures.
Gross margin:
Strong at ~67–70%. A phenomenal figure for a hardware manufacturer, underscoring its extreme pricing power due to its “only-one” technology.
Operating profitability: The operating margin remains consistently in the range of 22–25%. Asahi continues to consistently reinvest significant funds in R&D and capacity expansion (e.g., plants in Thailand and Vietnam) to keep imitators at bay.
Balance Sheet Strength: A flawless net-cash company (net debt/EBITDA ~ -0.4x). No significant debt risks, massive liquidity buffers. Growth is financed organically from operating cash flow.
3. Why is the stock exciting?
🚀1. Its “hidden champion” status: The market often underestimates the fact that Asahi is not just a standard supplier, but a systemically critical partner to the entire global surgical industry. Every minimally invasive surgery is a potential source of revenue for Asahi.
🚀2. Scaling & Capacity Expansion: The new production facilities in Thailand and Vietnam are increasingly coming online. Economies of scale are supporting the gross margin despite global cost pressures.
🚀3. Robotics as a Future Technology: Asahi is gearing up for robot-assisted surgery. As robots replace the surgeon’s hand, the demand for even more precise, sensor-equipped wire technology will rise—precisely Asahi’s area of expertise.
🚀4. Demographics as an Irrefutable Tailwind: The world’s aging population requires more cardiological, vascular, and neurovascular procedures. This is secular growth that remains virtually unaffected by recessions.
4. Risks ⚠️
❗️Currency risks (JPY): As a Japanese exporter (>70% of revenue generated abroad), currency fluctuations (particularly EUR/JPY and USD/JPY) cause apparent fluctuations in the figures upon conversion.
❗️Valuation at current levels: At exchange rates around ~3,689 JPY (P/E ratio ~32x), short-term growth is already largely priced in. The margin of safety relative to the base-case fair value (~2,850 JPY) has narrowed.
❗️Regulation: Delays in approval processes for new medical devices worldwide (FDA/MDR) can occasionally extend the time-to-market for new innovations.
🎯 EARNINGS PREP: ASAHI INTECC $7747 (+1.42%)
Date: Thursday, August 13 / Friday, August 14, 2026 (Official IR slot: 3:30 p.m. Tokyo local time)
Reporting Period: Q4 & Full Year FY2026 (Fiscal year-end: June 30, 2026)
since the stock price is at ~3,689 JPY is trading near its all-time high and the bar is set high.
1. 📊 EXPECTATIONS
Since these are the full-year results (FY2026) including the new guidance for FY2027, the market is scrutinizing them extremely closely:
Consensus revenue (Q4): ~34.7 billion JPY
Consensus EPS (Q4): ~17.3 JPY
Full-Year Revenue FY2026: Target is ~136–138 billion JPY (~14–15% YoY growth)
FY2027 Guidance: Crucial for the stock’s performance. The market expects further double-digit earnings growth (>12%) for FY2027.
My personal conclusion & Reaper Bonus 🧐
Asahi Intecc $7747 (+1.42%) is, in my view, one of the most exciting examples of how a company can build a real moat in a small niche often overlooked by the general public. Not a speculative tech stock, but a highly profitable medtech powerhouse with tremendous technological expertise.
Earnings are due next week, and I’m firmly convinced that $7747 (+1.42%) it will once again deliver strong results and blow expectations out of the water. 🔥
💀Jack’s Verdict:
“Forget short-term hype. Asahi Intecc is the kind of stock you hold in your portfolio and watch mature over the years. They provide the tools without which modern cardiology would simply grind to a halt—regardless of whether Medtronic, Boston Scientific, or Edwards ultimately comes out on top. The balance sheet is rock-solid. The only downside right now: The market has rediscovered the stock’s quality and driven the price up to nearly ¥3,700. No reason for panic for existing investors, but anyone looking to buy now should wait patiently for market noise toward the ¥2,850 to ¥3,000range.”
Reaper Rating: 🟡 HOLD / ACCUMULATE ON DIPs
DIP-BUYING RANGE: ¥2,800–¥3,000
Reaper Score:
7.5 / 10
(Quality remains at 9/10; the score is temporarily capped at ~3,689 JPY due to the valuation).
@Get_Rich_or_Die_Tryin
@Tenbagger2024
@PikaPika0105
@Multibagger
@Raketentoni And of course, everyone else ✌️
Have a great weekend, everyone 🫶
